STOCK TITAN

Atomera Provides Third Quarter 2020 Results

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Atomera Incorporated (NASDAQ: ATOM) reported its Q3 2020 financial results, showing no revenue compared to $254,000 in Q3 2019. The net loss increased to $3.6 million, or ($0.19) per share. Adjusted EBITDA also worsened, reporting a loss of $2.7 million against $2.4 million a year prior. While the company bolstered its balance sheet with $8.6 million from its At-The-Market equity program, its cash reserves grew to $25.3 million. Management highlighted advancements in customer and R&D developments, with plans for a joint development agreement to accelerate commercialization.

Positive
  • Strengthened balance sheet with $8.6 million from ATM equity program.
  • Increased cash reserves to $25.3 million from $14.9 million at year-end 2019.
  • Progress towards a joint development agreement which could accelerate commercialization of MST.
Negative
  • Revenue of $0 in Q3 2020 compared to $254,000 in Q3 2019.
  • Net loss increased to $3.6 million in Q3 2020 from $3.1 million in Q3 2019.
  • Adjusted EBITDA loss increased to $2.7 million from $2.4 million year-over-year.

LOS GATOS, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Atomera Incorporated (NASDAQ: ATOM), a semiconductor materials and intellectual property licensing company focused on deploying its proprietary technology into the semiconductor industry, today provided a corporate update and announced financial results for the third quarter ended Sept. 30, 2020.

Company Highlights

  • Commenced MST deposition on 300mm wafers on new epi tool
  • Achieved further gains on MST-SP’s industry leading performance
  • Bolstered balance sheet with proceeds of At-The-Market (ATM) equity program

Management Commentary

“Atomera made excellent progress on customer and R&D developments in the third quarter,” said Scott Bibaud, President and CEO. “We believe we are drawing closer to a joint development agreement encompassing development, licensing and manufacturing, which we believe will decrease the time to commercialization of MST. As our 300mm wafer deposition capability comes online, paired with our new TCAD capabilities, we believe we are poised to accelerate customers’ time to production. With our ATM facility, we strengthened the balance sheet and positioned the Company for the next phase of growth.”

Third Quarter 2020 Financial Results

During the third quarter of 2020, revenue was $0, compared with $254 thousand in the third quarter of 2019. The Company incurred a net loss of $3.6 million, or ($0.19) per basic and diluted share, in the third quarter of 2020, compared to a net loss of $3.1 million, or ($0.19) per basic and diluted share, for the third quarter of 2019.  Adjusted EBITDA (a non-GAAP financial measure) in the third quarter of 2020 was a loss of $2.7 million compared to an adjusted EBITDA loss of $2.4 million in the third quarter of 2019.

The Company had $25.3 million in cash and cash equivalents as of Sept. 30, 2020, compared to $14.9 million as of December 31, 2019.   During the quarter, Atomera sold 845,730 shares under its ATM facility resulting in net proceeds of $8.6 million. The total number of shares outstanding was 21.0 million as of Sept. 30, 2020.

Third Quarter 2020 Results Conference Call and Webcast

Atomera will host a conference call today to discuss its financial results and recent progress.
Date: Thursday, Oct. 29, 2020
Time: 2:00 p.m. PT (5:00 p.m. ET)
Webcast: Accessible at www.atomera.com
Phone: (844) 263-8318 (domestic); +1 (213) 358-­0960 (international); passcode 6268059
Replay: Available until Nov. 5, 2020; (855) 859­-2056 (domestic); +1(404) 537­-3406 (international); passcode 6268059.

Note about Non­-GAAP Financial Measures
In addition to the unaudited results presented in accordance with generally accepted accounting principles, or GAAP, in this press release, Atomera presents adjusted EBITDA, which is a non­-GAAP financial measure. Adjusted EBITDA is determined by taking net loss and eliminating the impacts of interest, depreciation, amortization and stock-­based compensation. Our definition of adjusted EBITDA may not be comparable to the definitions of similarly-­titled measures used by other companies. We believe that this non-­GAAP financial measure, viewed in addition to and not in lieu of our reported GAAP results, provides useful information to investors by providing a more focused measure of operating results. This metric is used as part of the Company's internal reporting to evaluate its operations and the performance of senior management. A table reconciling this measure to the comparable GAAP measure is available in the accompanying financial tables below.

About Atomera Incorporated
Atomera Incorporated has developed Mears Silicon Technology™ ("MST®"), which increases performance and power efficiency in semiconductor transistors. MST can be implemented using equipment already deployed in semiconductor manufacturing facilities and is complementary to other nano-­scaling technologies already in the semiconductor industry roadmap.

Safe Harbor
This press release contains forward­-looking statements concerning Atomera Incorporated, including statements regarding the prospects for the semiconductor industry generally and the ability of our MST technology to significantly improve semiconductor performance. Those forward­-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (1) the fact that, to date, we have only recognized minimal engineering services and licensing revenues and we have not yet commenced principal revenue producing operations or entered into a definitive royalty-based manufacturing and distribution license agreement with regard to our MST technology, thus subjecting us to all of the risks inherent in an early-stage enterprise; (2) risks related to our ability to advance the licensing arrangements with our initial integration licensees, Asahi Kasei Microdevices, ST Microelectronics and our fabless licensee, to royalty-based manufacturing and distribution licenses or our ability to add other licensees; (3) risks related to our ability to raise sufficient capital, as and when needed, to pursue the further development, licensing and commercialization of our MST technology; (4) impact of the coronavirus pandemic on our customers, partners, internal operations and market conditions, including our ability to access financial markets on favorable terms, (5) our ability to protect our proprietary technology, trade secrets and know-­how and (6) those other risks disclosed in the section "Risk Factors" included in our Prospectus Supplement filed pursuant to Rule 424(b)(5) with the SEC on September 2, 2020. We caution readers not to place undue reliance on any forward­-looking statements. We do not undertake, and specifically disclaim any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

-- Financial Tables Follow --

 
Atomera Incorporated
Condensed Balance Sheets
(in thousands, except per share data)
       
  September 30,  December 31, 
  2020  2019 
  (Unaudited)     
ASSETS        
         
Current assets:        
Cash and cash equivalents $25,297  $14,871 
Prepaid expenses and other current assets  181   132 
Total current assets  25,478   15,003 
         
Property and equipment, net  87   63 
Operating lease right-of-use asset  735   161 
Long-term prepaid rent  450    
Security deposit  13   13 
         
Total assets $26,763  $15,240 
         
LIABILITIES AND STOCKHOLDERS’ EQUITY        
         
Current liabilities:        
Accounts payable $563  $315 
Accrued expenses  234   145 
Accrued payroll related expenses  511   819 
Current operating lease liability  92   152 
Deferred revenue     37 
Total current liabilities  1,400   1,468 
         
Long term operating lease liability  631    
         
Total liabilities  2,031   1,468 
         
Commitments and contingencies        
         
Stockholders’ equity:        
Preferred stock, $0.001 par value, authorized 2,500 shares; none issued and outstanding at September 30, 2020 and December 31, 2019.      
Common stock, $0.001 par value, authorized 47,500 shares; 20,971 and 17,117 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively.  21   17 
Additional paid-in capital  170,975   149,017 
Accumulated deficit  (146,264)  (135,262)
Total stockholders’ equity  24,732   13,772 
         
Total liabilities and stockholders’ equity $26,763  $15,240 
         


 
Atomera Incorporated
Condensed Statements of Operations
(Unaudited)
(in thousands, except per share data)
                 
  Three Months ended
September 30,
  Nine Months ended
September 30,
 
  2020  2019  2020  2019 
Revenue $  $254  $62  $395 
Cost of revenue     (204)  (13)  (224)
Gross margin     50   49   171 
                 
Operating expenses                
Research and development  2,049   1,746   6,197   5,930 
General and administrative  1,322   1,239   4,247   4,048 
Selling and marketing  208   240   648   712 
Total operating expenses  3,579   3,225   11,092   10,690 
                 
Loss from operations  (3,579)  (3,175)  (11,043)  (10,519)
                 
Other income                
Interest income  1   89   41   265 
Total other income  1   89   41   265 
                 
Net loss $(3,578) $(3,086) $(11,002) $(10,254)
Net loss per common share, basic and diluted $(0.19) $(0.19) $(0.61) $(0.66)
                 
Weighted average number of common shares outstanding, basic and diluted  19,337   16,567   18,028   15,597 
                 


 
Atomera Incorporated
Reconciliation to Non-GAAP EBITDA
(Unaudited)
       
  Three Months Ended
September 30,
  Nine Months Ended
September 30,
 
  2020  2019  2020
  2019 
                 
Net loss (GAAP) $(3,578) $(3,086) $(11,002) $(10,254)
Add (subtract) the following items:               
Interest income  (1)  (89)  (41)  (265)
Depreciation and amortization  11   12   32   33 
Warrant modification        139    
Stock-based compensation  829   798   2,224   2,280 
Adjusted EBITDA (non-GAAP) $(2,739) $(2,365) $(8,648) $(8,206)
                 

Investor Contact:
Bishop IR
Mike Bishop
(415) 894-9633
investor@atomera.com

FAQ

What were Atomera's financial results for Q3 2020?

In Q3 2020, Atomera reported $0 in revenue, a net loss of $3.6 million, and an adjusted EBITDA loss of $2.7 million.

How much cash did Atomera have by September 30, 2020?

As of September 30, 2020, Atomera had $25.3 million in cash and cash equivalents.

What is Atomera's stock symbol?

Atomera is traded under the stock symbol ATOM on NASDAQ.

Did Atomera report any revenue growth in Q3 2020?

No, Atomera reported no revenue in Q3 2020, a decrease from $254,000 in Q3 2019.

What significant developments did Atomera achieve in Q3 2020?

Atomera commenced MST deposition on 300mm wafers and made progress towards a joint development agreement.

Atomera Incorporated

NASDAQ:ATOM

ATOM Rankings

ATOM Latest News

ATOM Stock Data

234.83M
27.43M
4.69%
22.88%
13.48%
Semiconductor Equipment & Materials
Semiconductors & Related Devices
Link
United States of America
LOS GATOS